Best Antidepressant for Depression in Anorexia Nervosa
For weight-restored patients with anorexia nervosa who remain depressed, fluoxetine 60 mg daily is the preferred antidepressant, as it reduces relapse risk and improves depressive symptoms without promoting weight gain. 1, 2
Treatment Algorithm Based on Weight Status
During Acute Malnutrition (Underweight Phase)
- Avoid antidepressants as monotherapy - they lack efficacy during active starvation and nutritional rehabilitation 3, 4
- The neurobiological changes from malnutrition render antidepressants largely ineffective
- Focus on weight restoration first through nutritional rehabilitation and psychotherapy 1
After Weight Restoration
First-line choice: Fluoxetine 60 mg daily 1, 2
- Most robust evidence for relapse prevention in weight-restored AN patients
- Particularly effective in those with moderate-to-severe depression (BDI >20) 2
- Recent 2025 data shows fluoxetine reduces relapse risk by 54% in depressed, weight-restored patients (HR=0.46) 2
- Weight-neutral to mild weight loss profile - critical advantage in AN population 5
Alternative options if fluoxetine fails or is not tolerated:
- Sertraline - weight-neutral long-term, may assist with relapse prevention 5, 3
- Citalopram - weight-neutral profile 6, 3
- Mirtazapine - consider only if weight gain is clinically desired, as it promotes appetite and weight gain 6, 7
Critical Contraindications and Cautions
Absolutely avoid:
- Bupropion - contraindicated due to seizure risk in malnourished patients 3
- Tricyclic antidepressants - dangerous in underweight patients due to cardiac risks 3
- MAO inhibitors - unsafe in this population 3
Use with extreme caution:
- Paroxetine - highest weight gain risk among SSRIs 6, 5
- Amitriptyline - most weight-promoting tricyclic 6, 5
Key Clinical Considerations
Timing Matters
The 2023 APA Eating Disorders Guideline emphasizes that antidepressants should be added to psychotherapy, not used as sole treatment 1. The most recent evidence (2025) demonstrates fluoxetine's efficacy is specifically in weight-restored patients with persistent depression 2.
Depression Severity as Predictor
Patients with moderate-to-severe depression (BDI >20) show significantly better response to fluoxetine than those with mild depression 2. This suggests screening depression severity should guide medication decisions.
Weight Profile Priority
In AN, the weight effects of antidepressants become a primary safety concern, not just a side effect. Weight-neutral or weight-loss-promoting agents (fluoxetine, sertraline) are strongly preferred over weight-promoting options (paroxetine, mirtazapine, amitriptyline) 5.
Common Pitfalls to Avoid
- Starting antidepressants during acute malnutrition - wait until weight restoration is achieved 3, 4
- Using antidepressants as monotherapy - always combine with eating disorder-focused psychotherapy 1
- Selecting weight-promoting antidepressants - this can trigger relapse and treatment dropout 5
- Inadequate dosing - fluoxetine requires 60 mg daily for AN, higher than typical depression dosing 1
- Premature discontinuation - continue for at least 12 months after weight restoration to prevent relapse 1
Monitoring Requirements
- Assess depression severity at baseline and regularly (every 2-4 weeks initially) 2
- Monitor weight weekly during early treatment 1
- Screen for suicidal ideation, particularly in first 1-2 months 8, 9
- Evaluate eating disorder symptoms alongside mood symptoms 2
The evidence strongly supports that fluoxetine 60 mg daily after weight restoration is the most appropriate choice, particularly for patients with persistent moderate-to-severe depression, given its dual benefits for relapse prevention and mood improvement without compromising weight maintenance.